Light Chain Bioscience | Novimmune SA Alternatives & Competitors

12 companies similar to Light Chain Bioscience | Novimmune SA — Light Chain Bioscience – A brand of Novimmune SA

Ensem Therapeutics

Kinetic Ensemble™ Platform for Precision Medicine

21 Series A $77.00M

Waltham, United States

Pentixapharm AG

improves the life of patients with malignant diseases through targeted molecular diagnosti...

37 Series A $15.00M

Wurzburg, Germany

Biotechnology Health Care +2

Myricx Bio

Developing a new class of ADCs based on NMT inhibition to treat cancer

36 Undisclosed $1.59B

London, United Kingdom

Biotechnology Health and Wellness +1

NiKang Therapeutics Inc.

37 Series C $260.00M

Wilmington, United States

Biotechnology Health Care

Track all Light Chain Bioscience | Novimmune SA competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Indi Molecular

Indi Molecular is an emerging life sciences company developing synthetic molecules with an...

2 Series A $11.50M

Culver City, United State...

Biotechnology Health Care

RayzeBio

Targeted innovative radiopharmaceuticals for cancer

258 Acquired $4.78B

San Diego, United States

Biotechnology Health Care +2

ONCOCROSS Co., Ltd.

AI, drug discovery development, biotechnology, indication expansion, rare disease, intract...

18 Corporate Round $18.00B

Seoul, Korea South

Biotechnology Pharmaceutical

Crossbow Therapeutics, Inc

Established antibody engineering to target the untapped universe of intracellular cancer t...

45 Series B $157.00M

Cambridge, United States

Biotechnology Health Care +1

DEM Biopharma, Inc.

Novel Target for Solid Tumors

20 Unknown $70.00M

Cambridge, United States

Biotechnology Life Sciences +1

Accutar Biotech

Employ AI to Revolutionize Drug Discovery

40 Series Unknown $77.45M

Brooklyn, United States

AI Biopharma +2

Exelixis

Exelixis works on discovering, developing, and commercializing therapies for the treatment...

1566 IPO $340.26M

Alameda, United States

Biotechnology

Celyad Oncology

19 Post Ipo Equity $135.80M

Belgium

Biotechnology Health and Wellness +1

About Light Chain Bioscience | Novimmune SA

Light Chain Bioscience – A brand of Novimmune SA

Services

Development of bispecific therapeutics, Safe and selective targeting of CD47 and CD28, Antibody-based therapeutic solutions

Target Customers

Oncologists, Pharmaceutical companies, Research institutions

Taxonomy

Bispecific Antibodies, Multispecific Antibodies, Antibody Drug Discovery, Kappa-Lambda-Body Technology, Native Human Antibodies, Preclinical Drug Candidates, Clinical Drug Candidates, Immunology, Drug Development, Novel Therapeutics, Antibody Therapeutics, Biotechnology Award Winner

Business Model

B2B, Platform, API

Revenue Model

Licensing, Product Sales, Service Fee

Frequently Asked Questions

Top alternatives to Light Chain Bioscience | Novimmune SA include Ensem Therapeutics, Pentixapharm AG, Myricx Bio, NiKang Therapeutics Inc., Indi Molecular. These companies serve similar markets and are frequently compared.

Bounce Watch tracks 12 companies similar to Light Chain Bioscience | Novimmune SA based on industry overlap, target customers, and business model.

Light Chain Bioscience – A brand of Novimmune SA

Don't just read about them. Follow them.

BounceWatch watches Light Chain Bioscience | Novimmune SA and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

Light Chain Bioscience | Novimmune SA Profile Ensem Therapeutics Alternatives Pentixapharm AG Alternatives Myricx Bio Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at Light Chain Bioscience | Novimmune SA on 12 Mar 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.